MedTrace Logo

Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)

NCT01662635 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2019-01-09

Study results available
· View outcomes & findings →

Summary

Because ALK-positive lung cancer constitutes less than 5% of all lung cancers, it is critically important to select those patients who are more likely to have the ALK mutation. Clinical characteristics of patients with mutations in the target gene should also be known, so that the incidence of a given target mutation is established in a specific population. There is not incidence known in Mexican population, but it is believed it is greater.

Conditions

  • Non Small-cell Lung Cancer

Sponsors & Collaborators

  • Instituto Nacional de Cancerologia de Mexico

    lead OTHER

Principal Investigators

  • Oscar Arrieta, MD · Instituto de Cancerología

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01662635 on ClinicalTrials.gov